Lifecome Biochemistry Co.,Ltd.

XSEC:002868 Stock Report

Market Cap: CN¥2.5b

Lifecome BiochemistryLtd Valuation

Is 002868 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002868 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 002868's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 002868's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002868?

Key metric: As 002868 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002868. This is calculated by dividing 002868's market cap by their current revenue.
What is 002868's PS Ratio?
PS Ratio4.3x
SalesCN¥581.34m
Market CapCN¥2.48b

Price to Sales Ratio vs Peers

How does 002868's PS Ratio compare to its peers?

The above table shows the PS ratio for 002868 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.7x
300313 Xinjiang Tianshan Animal Husbandry Bio-engineering
13.7xn/aCN¥2.0b
688221 Frontier Biotechnologies
20.8xn/aCN¥2.8b
688488 Jiangsu Aidea Pharmaceutical
9.4x42.1%CN¥3.9b
603739 Qingdao Vland Biotech
2.6x8.6%CN¥3.3b
002868 Lifecome BiochemistryLtd
4.3xn/aCN¥2.5b

Price-To-Sales vs Peers: 002868 is good value based on its Price-To-Sales Ratio (4.3x) compared to the peer average (11.7x).

Price to Sales Ratio vs Industry

How does 002868's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
603716 Thalys Medical Technology Group
0.8xn/aUS$211.90m
No more companies available in this PS range
002868 4.3xIndustry Avg. 7.5xNo. of Companies8PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 002868 is good value based on its Price-To-Sales Ratio (4.3x) compared to the CN Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 002868's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002868 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002868's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%